HRT pellets for perimenopause: what the evidence actually shows

What's this video probably claiming?

Based on the caption, @ashleaf_plantmama is sharing a first-person account of starting testosterone pellet therapy during what appears to be perimenopause. She's framing low testosterone as something measurable and clinically significant, positioning pellets as a more convenient alternative to weekly injections, and describing starting at a low-to-moderate dose to gauge her body's response. At two weeks in, she's likely reporting early impressions, possibly energy shifts, mood changes, or libido differences. This is a common format on wellness TikTok: relatable, hopeful, and light on pharmacokinetics. The implicit message is that pellets are a smooth, low-effort delivery system that works. That framing deserves some scrutiny before 49,500 people take it as gospel.

What does the science actually show?

Testosterone pellets are real medicine with a real evidence base, but it's thinner and messier than pellet clinics tend to advertise. A 2019 review by Glaser and Dimitrakakis in Maturitas found pellets can achieve stable serum testosterone levels over 3-6 months, which is a genuine pharmacokinetic advantage over short-acting injectables. However, a 2021 systematic review in Menopause by Islam et al. noted that pellet dosing for women lacks standardized protocols, and supraphysiologic testosterone levels, meaning levels above normal female range, were observed in a meaningful subset of patients. The FDA has not approved any testosterone pellet product specifically for women. Compounded pellets fall outside standard pharmaceutical manufacturing oversight, which matters for dose consistency. Two weeks is also nowhere near enough time to assess steady-state hormone levels, which typically require 4-6 weeks minimum.

Where does the social media noise diverge from clinical reality?

The biggest gap is around pellet convenience being conflated with pellet safety and precision. TikTok wellness content tends to present pellets as a set-it-and-forget-it solution, but the inability to adjust the dose after insertion is a real clinical limitation. If levels run high, there is no recall option. You wait it out. Glaser et al. (2013, Maturitas) reported androgenic side effects, including acne, hair thinning, and voice changes, in a subset of female patients receiving pellets. These are dose-dependent and harder to manage than with gels or patches, where dose adjustment is straightforward. The framing of "basically non-existent" testosterone as inherently pathological is also worth pushing back on. Female testosterone reference ranges are not well-standardized, and the Endocrine Society's 2014 clinical guidelines explicitly stated there is insufficient evidence to recommend testosterone therapy for women based on a lab number alone, absent symptoms.

What should you actually know?

If you are in perimenopause and genuinely symptomatic, testosterone therapy may be a reasonable option to discuss with a qualified clinician, but the delivery method matters and so does monitoring. A 2023 position statement from the Menopause Society acknowledged that testosterone can improve hypoactive sexual desire disorder in postmenopausal women, but noted that evidence for other claimed benefits, including energy, cognition, and body composition, remains limited. Pellets are not inherently superior to other delivery methods. Gels and patches allow dose titration. Injections, despite the weekly schedule, offer measurable control. Any evaluation should include a full hormone panel, a symptom assessment, and follow-up labs at 6-8 weeks post-insertion, not a two-week TikTok check-in. Forming a treatment plan based on another person's early experience with an unmonitored compounded product is a clinical risk, not a wellness strategy.